TheraVet Reports Significant Success of Its Last Educational Webinar on Canine Osteosarcoma Co-Organized With Veterinary Instrumentation

Regulatory News:

TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, organized on December 18, 2023, in collaboration with Veterinary Instrumentation, the exclusive BIOCERA-VET distributor in United Kingdom and Ireland, its last educational webinar of the year 2023.

The webinar entitled “Primary bone tumor, what now?” was presented by 2 experts: Dr James Elliot (BVM&S CertSAM Dip ECVIM-CA-RO (Oncology & Radiation Oncology) DACVR (RO) MRCVS, European Specialist in Small Animal Oncology & Radiation Oncology, American Specialist in Veterinary Radiation Oncology, RCVS Recognised Specialist in Veterinary Oncology) and Dr Ciarán Jones (MVB, MRCVS, MS, Dipl. ACVS, Dipl. ECVS).

During this webinar, management of canine osteosarcoma was presented from the up-to-date non-surgical to surgical management including the cementoplasty using BIOCERA-VET as a new and promise alternative of limb-sparing surgical procedure. For this last edition of the year 2023, 520 vet surgeons were registered and 203 were attending live.

The content of the webinar was appreciated by the attendees with a high average rating (8.4 out of 10) who judged it very useful and with very positive feedback: “An excellent overview of current state of the art OSA treatment”; “Excellent webinar, very thought provoking”; “Very interesting and concise”; “Excellent speakers and great choice of topic”.

About TheraVet SA
TheraVet is a veterinary biotechnology company specializing in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth Paris and Brussels, has its head office in Belgium (Gosselies) with a US subsidiary.
For more information, visit the TheraVet website or follow us on LinkedIn / Facebook / Twitter

About BIOCERA-VET
In close collaboration with an international scientific board, THERAVET has developed a new line of calcium-phosphate and biological bone substitutes, BIOCERA-VET. BIOCERA-VET is a full range of innovative, easy-to-use, efficient & cost-effective bone substitutes indicated in bone surgeries where a bone graft is required and as a palliative alternative in the management of canine osteosarcoma. Based on extremely promising clinical results, this line offers the possibility of a better, more convenient and more efficient orthopedic surgery.
BIOCERA-VET is declined in different lines:

• BIOCERA-VET BONE SURGERY RTU, a ready-to-use highly injectable self-hardening calcium-phosphate cement
• BIOCERA-VET SMARTGRAFT, a naturally osteoconductive bone graft
• BIOCERA-VET GRANULES, an affordable biocompatible calcium-phosphate bone substitute
• BIOCERA-VET OSTEOSARCOMA RTU, a ready-to-use highly injectable calcium-phosphate bone substitute for cementoplasty
• BIOCERA-VET COMBO-CLEAN, a local and long-lasting antibiotic delivery calcium-phosphate bone substitute

For more information, visit BIOCERA-VET website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240103264000/en/

The TheraVet Stock at the time of publication of the news with a fall of -79,68 % to 1,325EUR on Frankfurt stock exchange (03. Januar 2024, 17:35 Uhr).